A Phase Ib/IIa Trial of Panobinostat in Combination With Trastuzumab in Adult Female Patients With HER2 Positive Metastatic Breast Cancer Whose Disease Has Progressed During or Following Therapy With Trastuzumab
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine the dose of oral panobinostat plus trastuzumab combination
throughout the study
No
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
United States: Food and Drug Administration
CLBH589C2204
NCT00567879
April 2008
May 2011
Name | Location |
---|---|
Novartis Investigative Site | Philadelphia, Pennsylvania 19111-2497 |
Novartis Investigative Site | Sacramento, California 95817 |
Novartis Investigative Site | St. Louis, Missouri 63110 |
Novartis Investigative Site | Cleveland, Ohio 44195 |
Novartis Investigative Site | Denver, Colorado 80218 |
Novartis Investigative Site | Baltimore, Maryland 21201 |
Novartis Investigative Site | Norwalk, Connecticut 06856 |